Details for New Drug Application (NDA): 207923
✉ Email this page to a colleague
The generic ingredient in SEEBRI is glycopyrrolate. There are seventeen drug master file entries for this compound. Fifty-seven suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
Summary for 207923
Tradename: | SEEBRI |
Applicant: | Novartis |
Ingredient: | glycopyrrolate |
Patents: | 2 |
Medical Subject Heading (MeSH) Categories for 207923
Profile for product number 001
Expired US Patents for NDA 207923
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | 8,580,306 | ⤷ Subscribe |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | 7,736,670 | ⤷ Subscribe |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | 8,435,567 | ⤷ Subscribe |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | 6,521,260 | ⤷ Subscribe |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | 8,048,451 | ⤷ Subscribe |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | 8,956,661 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription